Randox has received regulatory CE Mark approval for its STI Multiplex Array, a new diagnostic weapon in the battle to control sexually transmitted infections (STIs).
STIs are on the increase worldwide, affecting 25-30% of young adults, and existing technologies and screening programmes are finding it hard to cope with the demand.
To avoid preventable health complications and to encourage more responsible sexual health practices, the STI Multiplex Array can simultaneously detect 10 of the most prevalent STIs from a single urine or swab sample in a single test within five hours. This includes chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis, Treponema pallidum (syphilis), Herpes simplex 1 & 2, Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum and Haemophilus ducreyi.
In addition to providing the most comprehensive STI screen available, testing for multiple STI pathogens can also identify secondary infections, which are present in greater numbers than previously thought, and allow specific treatments for all infections diagnosed.
